Literature DB >> 8618440

Cloning and characterization of the human tartrate-resistant acid phosphatase (TRAP) gene.

E Fleckenstein1, W Dirks, U Dehmel, H G Drexler.   

Abstract

The expression and protein structure of the tartrate-resistant acid phosphatase (TRAP), an iron-containing lysosomal glycoprotein in cells of the mononuclear phagocyte system, have been analyzed extensively in the past. In some diseases, like hairy cell leukemia and Gaucher's disease, cytochemically detected TRAP expression is used as a disease-associated marker. In this paper we describe the isolation of a genomic cosmid clone of the human TRAP gene. Restriction mapping revealed a 22-kb insert and the complete genomic structure of the TRAP gene. A 6-kb HindIII-fragment harboring the entire TRAP gene was subcloned and the 5'-flanking region of 3026 bp was sequenced. Analysis of the sequence data showed the presence of potential transcription factor binding sites. Two transcriptional start sites were identified in the untranslated exon 1 at positions -349 and -347 bp relative to the translational start codon. Linked to a luciferase-encoding reporter gene the 5'-flanking region was sufficient to direct transcription in the heterologous cell line BHK-21. Treatment of the transfected cells with different modulators of the intracellular iron content showed that regulation of TRAP expression is dependent on iron. In summary, these data imply a possible functional role of the TRAP gene product either in the storage or the transport of iron.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8618440

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  3 in total

1.  Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice.

Authors:  Xing Shen; Chao Wan; Girish Ramaswamy; Mahendra Mavalli; Ying Wang; Craig L Duvall; Lian Fu Deng; Robert E Guldberg; Alan Eberhart; Thomas L Clemens; Shawn R Gilbert
Journal:  J Orthop Res       Date:  2009-10       Impact factor: 3.494

Review 2.  Desferoxamine (DFO)--mediated iron chelation: rationale for a novel approach to therapy for brain cancer.

Authors:  Pouya N Dayani; Maria C Bishop; Keith Black; Paul M Zeltzer
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

3.  Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use.

Authors:  Haye H van der Wal; Niels Grote Beverborg; Kenneth Dickstein; Stefan D Anker; Chim C Lang; Leong L Ng; Dirk J van Veldhuisen; Adriaan A Voors; Peter van der Meer
Journal:  Eur Heart J       Date:  2019-11-21       Impact factor: 29.983

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.